On 4 February, the European External Action Service – the European Union’s diplomatic service – published an article on the EU-India cooperation on health and the EU co-funded project – In Silico Trial for Tuberculosis Vaccine (StriTuVaD).
The article outlines the main outcomes of the first meeting of the consortium of European, American and Indian scientists that took place in New Delhi, in January, hosted by the All India Institute of Medical Sciences (AIIMS), the Indian lead scientific partner. During this meeting, the consortium discussed plans for the execution of the clinical trial where two new therapeutic vaccines will be tested and which will be used to quantify the predictive accuracy of the computer model used. It is anticipated that the information obtained by the clinical trial will help the future regulatory qualification of in silico trials methods which would reduce the costs for the development of more effective therapies for tuberculosis.
Led by Etna Biotech, an innovative R&D company based in the south of Italy, the STriTuVaD consortium is composed by:
Full information on the project can be found here